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Urothelial differentiation in chronically urine-deprived blad-
ders of patients with end-stage renal disease.
Background. It is unknown whether normal bladder voiding
function, or soluble factors present in urine, contribute to the
maturation and maintenance of the differentiated state of the
uroepithelial cell lining of the lower urinary tract.
Methods. We used the urothelium of anuric patients on
long-term hemodialysis, sampled at the time of renal
transplantation, to investigate the expression of urothe-
lial differentiation-associated antigens, including uroplakins
(UPIa, UPIb, UPII, and UPIIIa), cytokeratin isotypes (CK7,
CK8, CK13, CK14, CK17, CK18, and CK20), nuclear hor-
mone receptors [peroxisome proliferators activated receptor-
c (PPAR-c) and retinoid X receptor-a (RXR-a)], and a cell
cycle marker (Ki-67). To determine whether urinary metabo-
lites of the arachidonic pathway could induce urothelial differ-
entiation, cultured normal human urothelial (NHU) cells were
treated with 15-deoxy-12, 14-prostaglandin J2 (15d-PGJ2) and
prostaglandin J2 (PGJ2). The expression levels of the markers
of differentiation, the uroplakins, were assessed by ribonuclease
protection assay.
Results. When compared in a blinded analysis against control
normal urothelium, no significant changes were found in the
expression or localization patterns of any of the antigens studied
in the anuric patients. Furthermore, neither 15d-PGJ2 nor PGJ2
were able to induce expression of the UPII gene in NHU cells,
in contrast to cultures exposed to the pharmacologic PPAR-c
agonist, troglitazone.
Conclusion. These data provide prima facie evidence that ex-
ogenous urine-derived factors do not modulate the differentia-
tion program in urothelium, suggesting that other urothelial- or
serum-derived factors are likely to be involved. These findings
are important in understanding postdevelopmental maturation
and functional relationships in urologic tissues of the adult or-
ganism.
Human urothelium undergoes a complex differentia-
tion process that culminates in the formation of asymmet-
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ric unit membrane plaques in the apical membrane of the
terminally differentiated superficial cells. The asymmetric
unit membrane, which is assembled by the interactions of
at least four integral transmembrane uroplakin proteins,
UPIa, UPIb, UPII, and UPIIIa, is regarded as an unequiv-
ocal marker of terminal urothelial differentiation [1]. The
critical role of the asymmetric unit membrane in develop-
ing an effective urinary barrier is illustrated in the UPIIIa
null mouse, which has a “leaky” urothelium associated
with aberrant plaque formation [2, 3]. However, the in
vivo factors that direct and maintain the normal urothe-
lial differentiation program are poorly understood.
Using a well-characterized culture system for normal
human urothelial (NHU) cells [4, 5], we have recently
shown that synthetic high-affinity activators of peroxi-
some proliferators activated receptor-c (PPAR-c) induce
a program of gene expression changes leading to the ex-
pression of markers of terminal urothelial differentia-
tion, including cytokeratin (CK) 20 [6] and the uroplakins
[7]. The PPAR-c–induced differentiation was contingent
upon coinhibition of an epidermal growth factor receptor
(EGFR)-mediated autocrine signaling pathway, which is
active in proliferating urothelial cells [7]. This implies a
critical balance in the regulation of proliferation and dif-
ferentiation in urothelium, an epithelium characterized
by a low constitutive turnover rate, but high proliferative
and regenerative capacity.
PPAR-c belongs to the superfamily of nuclear hor-
mone receptors and is a ligand-activated transcription
factor that requires heterodimerization with the retinoid
X receptor-a (RXR-a) to bind specific PPAR response
elements (PPRE) in the promoter region of target genes
[8, 9]. PPAR-c expression has been described in the ma-
ture urothelium of mice, rabbits, and humans and has also
been identified in the developing urothelium of the mouse
urogenital sinus [10–12]. In mature urothelium, the most
intense nuclear expression of PPAR-c is present in the
superficial cells [6, 13] a pattern that is obscured in con-
ditions of urothelial squamous metaplasia [6].
15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) has
been identified as a candidate natural ligand for PPAR-c
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Table 1. Patient details
Volume per day in mL
(micturation frequency Dialysis
Case Gender Age Anuria per 24 hours) months Histology Ki-67 index
1 M 22 Yes — 77 Normal 0
2 F 37 Yes — 19 Normal 0.1
3 M 28 Yes — 12 Normal 0.2
4 M 57 Yes — 17 Mild inflammation 0.2
5 F 61 Yes — 79 Normal 0.1
6 M 27 Yes — 56 Mild inflammation 0.04
7 M 37 No 350 (1) 34 Mild inflammation 0.2
8 M 40 No 300 (2) 30 Normal 0.1
9 F 58 No 50 (2) 26 Normal 0.1
10 M 37 No 500 (1) 19 Normal 0.1
and is the major prostaglandin present in urine [14]. This
implies that superficially positioned urothelial cells are
exposed to factors in urine that may be capable of acti-
vating the terminal urothelial differentiation program.
In this study we tested the hypothesis that factors
in urine, in particular urine-derived 15d-PGJ2 acting
through PPAR-c, are necessary for regulating and main-
taining a terminally differentiated urothelial phenotype.
For this purpose, bladder urothelia from patients on long-
term hemodialysis with no normal urine production were
compared to the urothelia from patients with normal
renal function, with respect to histomorphology, prolif-
eration (Ki-67 antigen) and the expression of antigens
associated with urothelial differentiation, including uro-
plakins, CKs, and PPAR-c. Finally, NHU cell cultures
were exposed to 15d-PGJ2 in the presence or absence
of EGFR inhibitors, in order to determine whether 15d-
PGJ2 could activate the terminal urothelial differenti-




The collection of all surgical specimens was approved
by the relevant Local Research Ethics Committee. Tis-
sues were fixed in 10% buffered formalin and processed
into paraffin wax for histology or immunohistochemistry.
Histopathologic assessment for each case was performed
on hematoxylin and eosin–stained sections using stan-
dard criteria for the evaluation of urothelium [15].
Open bladder mucosal biopsies were obtained from
ten consented patients (mean age 40 years; range 22 to
61 years) undergoing surgery for renal allograft trans-
plantation between 1998 and 1999. The biopsies orig-
inated from the vesicoureteric anastomosis site at the
superior-lateral aspect of the bladder. All patients had
end-stage renal disease (ESRD) and had been on main-
tenance hemodialysis for a minimum of 12 months (mean
dialysis time 37 months; range 12 to 79 months). All pa-
tients participating in the study answered questions about
continued residual urine production (i.e., amount and fre-
quency of diuresis per 24 hours) (Table 1). At the conclu-
sion of the study, patients were directly contacted about
urinary symptoms and in addition, patient medical his-
tory was reviewed regarding bladder function and any
novel lower urinary tract pathology.
Nine bladder biopsies were selected at random from a
bank of anonymous normal bladder controls. The spec-
imens had been taken from patients with no history
of renal function disorders and all had been classed as
showing a normal, intact mature urothelium with no ev-
idence of inflammation, ulceration, dysplasia, or malig-
nancy by histopathologic criteria. The clinical reasons
for cystoscopy were varied and included investigations
for hematuria, repeated atypical cells in urine, a previ-
ous history of low grade papillary urothelial carcinoma,
and pediatric patients undergoing reconstructive bladder
surgery.
Immunohistochemistry
Immunohistochemistry was performed using rabbit an-
tisera against UPIa (generously provided by T. Yoshiki,
Department of Urology, Shiga University of Medical
Science, Japan [16]), UPIb (the generous gift of W.
Adachi, Department of Ophthamology, Kyoto Prefec-
tural University of Medicine, Japan [17]) and mono-
clonal anti-UPIIIa (clone AU1) (purchased from Progen
Biotechnik, Heidelberg, Germany). CK expression was
localized using monoclonal antibodies to CK7 (clone
LP1K), CK8 (clone LE41), CK14 (clone LL002), CK19
(clone LP2K) (all supplied by Central Resources, Cancer
Research UK, London, UK), CK13 (clone IC7) (from
ICN Biomedical Inc., Basingstoke, UK), CK17 (clone E3,
supplied by Serotec, Kidlington, UK), CK18 (clone CY-
90) (from Sigma-Aldrich, Poole, UK), and CK20 (clone
Ks20.8) (supplied by Dako, Ely, UK). Monoclonal anti-
PPAR-c (clone E-8) and polyclonal anti-RXR-a (clone
D20) were obtained from Santa Cruz Biotechnology
(supplied by Autogen-Bioclear UK Ltd., Calne, UK), and
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monoclonal anti-Ki-67 (clone MIB-1) was supplied by
Dako. All antibodies were titrated prior to use.
Five micrometer sections were dewaxed in xylene
and rehydrated through graded alcohols. Endogeneous
peroxidase activity was inactivated in 3% (vol/vol) hy-
drogen peroxide for 10 minutes, followed by blocking of
endogenous avidin-binding sites using an avidin/biotin
kit (Vector Laboratories, Peterborough, UK), accord-
ing to the manufacturer’s protocol. Heat antigen re-
trieval, in which sections were boiled for 10 minutes in
10 mmol/L citric acid buffer, pH 6.0, in a microwave
oven, was required prior to labeling sections with anti-
bodies against CK7, CK8, CK18, UPIa, UPIb, UPIIIa,
RXR-a, and MIB-1. For antibodies against CK13, CK14,
CK17, and PPAR-c, heat antigen retrieval was followed
by an additional 1 minute of digestion of tissue sections
in 0.1% (wt/vol) trypsin in 0.1% CaCl2, pH 7.6, at 37◦C.
Antibodies for CK19 and CK20 required digestion for
10 minutes in trypsin in 10 mmol/L Tris-buffered saline,
pH 7.6. Immunohistochemistry for all antibodies, except
PPAR-c and RXR-a, was performed using an indirect
strepavidin ABC immunoperoxidase method (Dako), ac-
cording to the manufacturer’s recommendations. For the
detection of low-density PPAR-c and RXR-a antigens,
the more sensitive tyramide-based catalyzed signal am-
plification method [Dako Catalysed Signal Amplification
(CSA) peroxidase method] was applied. The manufac-
turer’s recommendations were followed, except that in
order to optimize the signal-to-noise ratio, the incuba-
tion in primary antibody was extended to 30 minutes and
the secondary antibody incubation and amplification pe-
riod were reduced to 5 minutes each. All labeling series
were performed with appropriate negative and positive
controls. Slides were counterstained with Mayer’s hemo-
toxylin, dehydrated and mounted in DPX (BDH, sup-
plied by Merck, Lutterworth, UK).
The specificity of the labeling characteristics of PPAR-
c achieved using the CSA Kit was assessed on mature
adipose tissue and large bowel mucosa. In large bowel,
the differentiated colonic epithelial cells facing the lumen
displayed intense nuclear labeling, whereas proliferating
cells located in the bases of the crypts labeled not at all, or
very weakly (data not shown). These results were consis-
tent with those described in mouse colonic mucosa [18].
Objective evaluation of expression patterns
and parameters
High power images (×400 magnification) were selected
from areas of intact, full-thickness urothelium and cap-
tured using a digital camera (JVC, KY-F55BE, Victor
Company of Japan) mounted on a light microscope (Zeiss
Axioplan 2; Carl Zeiss, Ltd., Welwyn Garden City, UK).
A high-quality print of a representative captured field
for all cases were ranked by two observers (J. Southgate
and J. Stahlschmidt), blinded to their origin, for label-
ing patterns of UPIa, UPIb, UPIIIa, CK20, and PPAR-c.
The Kruskal-Wallis nonparametric test was used to an-
alyze differences in the expression patterns between
“anuric,” “non-anuric,” and “control” categories. Rank-
ing was inferred from reference labeling patterns of nor-
mal urothelia.
The Ki-67–labeling index was assessed in areas of full-
thickness urothelium by counting the proportion of nuclei
with a positive (diffuse or punctate) Ki-67 nuclear label-
ing pattern [19]. The number of total nuclei assessed per
biopsy ranged from 800 to 3000.
Cell culture
NHU cells were isolated and established in culture as
finite cell lines, as previously detailed [4, 5]. Cells were
maintained in keratinocyte serum-free medium (KSFM),
containing bovine pituitary extract and EGF at the manu-
facturer’s recommended concentrations (Invitrogen Ltd.,
Paisley, UK) and 30 ng/mL cholera toxin (Sigma-Aldrich,
Poole, UK). NHU cell lines were maintained at 37◦C in a
humidified atmosphere of 5% CO2 in air and were used
for these studies between passages 3 and 5.
In order to determine whether 15d-PGJ2 or its
metabolic precursor, PGJ2, induce differentiation of
NHU cells, cells were treated with 15d-PGJ2 and PGJ2.
Experiments were performed using the optimized condi-
tions described previously [6, 7]. Briefly, NHU cells were
seeded at 4 × 104 cells/cm2 and grown to 70% confluence,
before being treated with 1 lmol/L to 5 lmol/L 15d-PGJ2
(Calbiochem-Novabiochem Biosciences Ltd., Notting-
ham, UK), 0.5 lmol/L to 20 lmol/L PGJ2 (Sigma-Aldrich,
Poole, UK) or 0.1 lmol/L to 5 lmol/L troglitazone (a gift
from Parke-Davis Pharmaceutical Research, Ann Arbor,
MI, USA) as positive control, or 0.01% (vol/vol) dimethyl
sulfoxide (DMSO) as negative (solvent) control. After
24 hours, the medium was removed and the cells were
maintained with 1 lmol/L EGFR inhibitor, PD153035
(Calbiochem-Novabiochem Biosciences Ltd.), which was
replenished with the medium every 2 days. Cell cultures
were harvested and assessed for uroplakin transcripts at
4 days.
Ribonuclease protection assays
To extract RNA from cell monolayers, TrizolTM (Invit-
rogen) was added to the cell monolayer (1 mL/10 cm2)
and the cell lysate was scraped into a centrifuge tube.
RNA was extracted as recommended by the manufac-
turer.
Part-length cDNA fragments of the coding region for
human UPIa, UPIb, UPII, UPIIIa, and GAPDH genes
were cloned into pGEM-T Easy (Promega, Southamp-
ton, UK), as described previously [20]. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as
an internal riboprobe control. 32P-labeled antisense
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transcripts of the cDNAs of interest were generated
from linearized plasmids using an In Vitro Transcription
Kit (Promega), according to the manufacturer’s proto-
col. After DNAse treatment, riboprobes were purified
by passage through Chromaspin 30-DEPC columns (BD
Biosciences Clontech UK, Oxford, UK).
Approximately 2 fmol of each riboprobe were mixed
and hybridized to 5 lg of total RNA using an RPAIII
Kit (Ambion Ltd., Huntingdon, Cambs, UK), according
to the manufacturer’s protocols. Products were separated
on 5% denaturing polyacrylamide gels (Sequagel) (from
Flowgen, Lichfield, UK), visualized by autoradiography
and quantified by means of a phosphorimager (Bio-Rad
GS-525 Molecular Imager System) (Hemel Hempstead,
UK).
RESULTS
Histologic sections of “control,” “anuric,” and “nona-
nuric” bladder urothelia were similar and revealed the
characteristic vertical organization pattern into three
well-defined cell layers. The urothelial thickness was be-
tween four to seven cell layers in all categories. Super-
ficial cells were the largest cells of either flattened or
rounded shape, often binucleated with large nuclei and
slightly open, sometimes vesicular chromatin and occa-
sional large nucleoli. There was no evidence of meta-
plastic changes or atypia. Mitotic figures were scanty
and observed in basal and intermediate cell layers. Occa-
sional intraurothelial lymphocytes were present and the
lamina propria contained occasional mononucleated in-
flammatory cells, including macrophages or mast cells.
Two “anuric” (56 and 36 months on dialysis) and one
“nonanuric” (17 months on dialysis) specimens showed
mild chronic inflammation of the urothelium and lam-
ina propria. No acute inflammatory cells, plasma cells, or
granulomata were identified. One control bladder biopsy
revealed von Brunn’s nests.
Uroplakin expression
All control urothelia reacted with the three antiuro-
plakin antibodies (Fig. 1, left column). UPIa and UPIIIa
showed highly consistent specificity, with intense pencil-
line labeling of the apical membrane. In areas of su-
perficial denudation, intermediate cells were not labeled
with UPIa or UPIIIa. UPIb was localized superficially in
all nine control specimens (see Fig. 1D), although two
of the cases revealed additional cytoplasmic labeling of
suprabasal and intermediate cells.
The two dialysis patient categories showed a very sim-
ilar pattern of labeling with the uroplakin antibodies
(Fig. 1, center and right columns). For UPIa and UPII,
analysis of the ranked series by Kruskal-Wallis statistics
revealed that there was no significant difference between
the control versus the dialysis patients (P > 0.99 for UPIa
and P > 0.92 for UPIIIa).
UPIb also showed two patterns of labeling: either
restricted to the luminal aspect of the superficial cell
(4/10 specimens) or additionally present throughout
the urothelium (6/10 specimens) (Fig. 1E and F). Full-
thickness UPIb expression was detected in the urothelia
of three fourths “nonanuric” patients and in half of the
anuric patients (3/6) (P = 0.05).
PPAR-c and RXR-a expression
Nuclear PPAR-c expression was observed in all con-
trols and all samples revealed a differentiation-associated
expression pattern with the strongest nuclear label-
ing in the superficial cell layer (Fig. 1M to O). In
the stroma, PPAR-c reacted with macrophages, nuclei
of smooth muscle cells, and endothelial cells. Overall,
the differentiation-associated expression of PPAR-c was
maintained in the two renal transplant categories. The
Kruskal-Wallis test revealed no differences in the expres-
sion patterns of PPAR-c for all three groups (P > 0.99).
RXR-a labeling patterns in control urothelia was sim-
ilar to PPAR-c, with a predominately diffuse labeling of
the nucleus, which varied in intensity. Punctate cytoplas-
mic labeling was generally more pronounced than seen
with PPAR-c (Fig. 1P to R). No differences with respect
to labeling patterns for RXR-a were apparent between
the three groups in a blinded analysis.
CK expression
CK expression patterns were in agreement with previ-
ous reports [21]. There was no difference in the urothelial
CK expression patterns between bladders with or with-
out residual urine or the control bladders. In particular,
there were no differences in the labeling patterns of basal
cells. No CK14 expression was identified, supporting the
absence of squamous metaplasia by histologic criteria. In
all samples, CK20 expression was confined to superficial
cells (Fig. 1J to L).
Ki-67 labeling indices
The Ki-67 labeling index was similar in both the
anuretic (mean 0.125%, median 0.15%, range 0.04% to
0.2%) and residual urine group (mean 0.106%, median
0.1%, range 0.0% to 0.2%) and was lower than in the
control group (mean 0.22%, median 0.2%, range 0.2%
to 0.3%) (Table 1).
Clinical follow-up
Posttransplant, all patients experienced reasonable
bladder function, defined as voiding three to seven times
of normal volume of urine per 24 hours. A 5-year clini-
cal follow-up revealed that two patients had since died of







Fig. 1. Immunhistochemical expression of uroplakins UPIa (A to C), UPIb (D to F), UPIIIa (G to I), CK20 (J to L), peroxisome proliferator-
activated receptor-c (PPAR-c) (M to O), and retinoid X receptor-a (RXR-a) (P to R) in controls (left column), “non-anuric” (middle column),
and “anuric” (right column) urothelium. All sections counterstained with hematoxylin [original magnification ×600; bar in (A) 100 lm]. Note the
preservation of the labeling patterns for UPIa (A to C), UPIIIa (G to I), CK20 (J to L, PPAR-c (M to O), and RXR-a (P to R) in all three groups.
UPIb (D to F) revealed the greatest variation in expression, which was also noted in control specimens. Note persistent decoration of the superficial
membrane region even in the case of cytoplasmic UPIb expression (E and F).
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Fig. 2. Effect of peroxisome proliferator-activated receptor (PPAR) ligands on uroplakins (UP) mRNA expression. (A) Normal human urothelial
(NHU) cells were pretreated for 24 hours in the absence or presence of troglitazone (TZ), 15-deoxy-12,14-prostagladin J2 (15d-PGJ2), and
prostaglandin J2 (PGJ2) at the concentrations indicated. Next, the cells were incubated for 4 days in medium treated with the epidermal growth
factor (EGF) receptor inhibitor, PD153035 (1 lmol/L). Medium was changed with “fresh” PD153035 added every 2 days. Total RNA was extracted
and 5 lg was hybridized with 32P-labeled human uroplakin UPIa, UPIb, UPII, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
probes. The samples were electrophoresed on a 5% polyacrylamide gel. (B) The uroplakin bands were quantified by means of a phosphorimager
and normalized against the GAPDH which was used to standardize for loading efficiency. Troglitazone at 5 lmol/L concentration was taken to be
100%.
causes unrelated to bladder-renal function. The remain-
der of the patients reported no symptoms regarding their
bladder function.
Effect of 15d-PGJ2, PGJ2, and troglitazone
on expression of uroplakin mRNA
NHU cells did not express UPIa, UPII, or UPIIIa un-
der normal culture conditions, although there was con-
stitutive expression of UPIb mRNA, in agreement with
previous reports [7, 20]. Previously, we have demon-
strated that the PPAR-c ligand, troglitazone, induces the
expression of UPIa and UPII, when EGF signaling is
blocked [7]. Treatment of EGFR-inhibited NHU cells
with 15d-PGJ2 or PGJ2 did not result in any increase in ex-
pression of mRNA for any of the uroplakins (Fig. 2A). As
a positive control, when EGFR-inhibited NHU cells were
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treated with troglitazone, there was a dose-dependent
induction of UPIa, UPIb, and UPII mRNA expression at
concentrations of troglitazone of up to 1 lmol/L (Fig. 2B).
DISCUSSION
PPAR-c signaling has been implicated in the differ-
entiation of adipocytes [22], carcinoma cell lines [23–25]
and more recently, NHU cells [6, 7]. In the latter case,
pharmacologic activation of PPAR-c in cultures of NHU
cells led to transcription of genes associated with termi-
nal urothelial cytodifferentiation and raises the interest-
ing question of how this relates to the in vivo situation.
Given the superficial accentuation of PPAR-c expression
and the presence in urine of the putative PPAR-c ago-
nist, 15d-PGJ2, it was considered that 15d-PGJ2 may act
through PPAR-c to induce urothelial differentiation in
superficially-positioned cells. Such a hypothesis is com-
pelling, as it would provide a mechanism for differentia-
tion and the development of urinary barrier function in
intermediate urothelial cells exposed to urine following
exfoliation of superficial cells.
Following the establishment of a predominately
differentiation-associated pattern for the expression of
PPAR-c and its heterodimerization partner RXR-a in
normal urothelium [6, 7], the rationale of this study
was to determine whether lack of exposure to normal
urine affected proliferation or the expression of urothe-
lial differentiation-associated markers. For this purpose,
the urothelium from patients on maintenance hemodial-
ysis for ESRD, with or without residual renal function,
was investigated. Our results suggest that urinary fac-
tors are inconsequential to the maintenance of urothelial
cytodifferentiation. Furthermore, as such bladders lack
physiologic filling and voiding cycles, cyclic mechanical
changes also appear unnecessary to maintain a differenti-
ated urothelium. Although the absolute number of spec-
imens studied was small, they came from a rigorously
selected group of patients with end-stage renal failure
and on dialysis for more than 2 years. We believe that the
lack of evidence for a change in the differentiation sta-
tus of the urothelium provides prima facie evidence that
bladder function is not involved in maintaining urothelial
differentiation.
In humans, uroplakins UPIa, UPII, and UPIIIa are
highly urothelium- and differentiation-specific [26] and
all revealed highly restricted immunolocalization to the
apical aspect of superficial cells. Only UPIb displayed a
degree of variable expression, showing an apical local-
ization consistent with its role in the asymmetric unit
membrane plaque, but with additional diffuse labeling
throughout the urothelium in some specimens. The find-
ing that UPIb showed the least differentiation-specific
profile is consistent with other data; the uroplakins ex-
ist as heterodimers in the asymmetric unit membrane
plaques and this state is obligate for all but UPIb, which
is therefore the only uroplakin to exist outside of the
asymmetric unit membrane plaque [2, 27]. Furthermore,
of all the uroplakin genes, UPIb is the least tissue- and
differentiation-restricted [26, 28] and is expressed by non-
differentiated NHU cell cultures and by 50% superficial
urothelial cell carcinomas [20]. It is unknown why UPIb is
less differentiation-restricted than the other uroplakins,
but it is possible that it may have alternative, nonasym-
metric unit membrane–related function(s), which have
yet to be elucidated. Nevertheless, there was no statis-
tical difference in UPIb expression pattern that related
to whether the urothelium had been exposed to normal
urine or not and a similar “broadening” of expression was
found in some normal control specimens. This implies
that changes in UPIb expression did not relate directly to
the deprivation of urine or other bladder function.
The identification of 15d-PGJ2 as the final metabolite
of the PGJ2 series (reviewed [29]) led to its recognition
as a candidate natural ligand of PPAR-c [30, 31], which is
present in human urine [32]. Men excrete approximately
152 ng/24 hours of urinary 15d-PGJ2, almost double the
amount excreted by females [14], although these gender-
related findings are not consistently reported [32]. In-
terestingly, the present study demonstrated that bladder
urothelium from patients on maintenance hemodialysis
for ESRD revealed a terminally differentiated urothelial
phenotype, independent of the duration of dialysis (maxi-
mum dialysis time 79 months), or the presence or absence
of intravesical residual urine due to residual renal func-
tion.
The study also demonstrated that the long-term ab-
sence of urinary factors had no effect on the quiescent
nature of urothelium. Anuric patients and patients with
residual renal function had on average the same propor-
tion of cells in the mitotic cell cycle (0.1%), which was
half that of the control group (average 0.2%).
The maintenance of a differentiation-associated ex-
pression pattern of PPAR-c and RXR-a in urothelium, in
the absence of urine, does not support the hypothesis that
urine-derived factors, including PGJ2 and 15d-PGJ2, are
necessary factors in the maintenance of a differentiated
urothelial phenotype. In vitro studies have generally used
15d-PGJ2 at concentrations in the micromolar range. The
median effective concentration (EC50) for 15d-PGJ2 to
promote efficient differentiation of C3H10T1/2 fibrob-
lasts to adipocytes was 7 lmol/L [30] and the effec-
tive concentration of 15d-PGJ2 for activation of PPAR-
c in gene reporter studies was 3 lmol/L [31]. Three
micromoles per liter was also the effective growth in-
hibitory concentration of 15d-PGJ2 for NHU cells in
vitro [11]. Nevertheless, even this concentration of 15d-
PGJ2 would be 5000 times higher than the presumed in
vivo concentration of 15d-PGJ2 in the urine of men, sug-
gesting that the concentrations in urine are biologically
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ineffective. Although prostaglandin transporters (PGT)
have recently been identified in man, Xenopus oocyte
transfection models for prostaglandin E2 (PGE2) were
only able to produce a maximum 15-fold concentration
gradient [33, 34]. Moreover, there is no PGJ2 transporter
gene expression reported in urothelium [34]. The role of
15d-PGJ2 as a physiologic ligand for PPAR-c is the sub-
ject of some controversy [34] and our results support the
view that it is not a strong candidate.
Nevertheless, the strong differentiation-associated ex-
pression of PPAR-c is highly suggestive of an involvement
in urothelial differentiation. One possible explanation
for the maintenance or expression of PPAR-c in urothe-
lium is that a PPAR-c–specific ligand is derived from
the urothelial cells themselves in an autocrine fashion,
since PPAR-c expression is self-regulated [34]. Jowsey
et al [35] determined gene expression of PPAR-c and
of prostaglandin D2 synthase (PGDS), the key enzyme
producing prostaglandins of the D and J series, and
demonstrated coexpression in a number of human tis-
sues and cell types, including adipose tissue, placenta,
prostate, and macrophages. Unfortunately, urothelium
was not included in their study. However, these data re-
veal the potential for de novo prostaglandin synthesis
in the context of PPAR-c expression in human epithelial
cells, and suggest that the endogenous production of fatty
acid metabolies, such as prostaglandins, may contribute
to PPAR-c signaling in vivo.
CONCLUSION
This is the first study to systematically investigate blad-
der urothelium from patients on maintenance hemodialy-
sis with normal bladder function and no history of urinary
symptoms. Studies assessing the urothelium of patients
with normal bladder function on maintenance dialysis
are sparse and have primarily focused on the develop-
ment of benign or malignant neoplastic lesions [36, 37].
Our results imply that urothelium is able to maintain its
highly differentiated phenotype and function over a long
period of time even in the absence of its usual environ-
mental interphase of urine or mechanotransduction and
suggest that other (intrinsic or extrinsic) factors must be
involved in regulating the differentiated phenotype.
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